University of Massachusetts

Medarex Inc.

Centers for Disease Control and Prevention

University System of Maryland

E. R. Squibb Sons, Inc.

Affinivax, Inc.

Charles Rupprecht

Gregory J. Babcock

Robert Mandell

William D., Jr. Thomas

Donna Ambrosino

Susan Sloan

Gregory Babcock

William D Thomas, Jr

Teresa J Broering

Robert Barry Mandell

Hector Javier Hernandez

Israel Lowy

Robert F Graziano

Hui-Fen Zhang

Deborah Molrine

Gregory J Babcock

Zuoshang Xu

Charles E Rupprecht

William D Thomas

Francis Michon

Richard Malley

George Rainer Siber

Alan S Cross

Raphael Simon

Sharon Tennant

Thomas Greenough

Katherine Luzuriaga

Mohan Somasundaran

John Sullivan

Susan Schonhoff

Theresa Broering

Jr Thomas William D

Alan Cross

William Thomas

Technologies for the prevention and/or treatment of nosocomial infections.

Immunogenic compositions

The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS.

Anti-SOD1 antibodies and uses thereof

Antibodies that specifically bind to toxins of, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

Antibodies against clostridium difficile toxins and uses thereof

Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Human antibodies against hepatitis C virus (HCV) and uses thereof

[object Object]

Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein.

Human antibodies against rabies and uses thereof

Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.

SARS nucleic acids, proteins, antibodies, and uses thereof

Growing community of inventors

Jamaica Plain, MA, United States of America

Donna Ambrosino